Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative ...

The FDA has given Viatris tentative approval for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.

The fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension is indicated for the treatment of HIV-1 infection in paediatric patients weighing at ...

The study was published today in a new dispersible formulation and an immediate-release tablet containing three medications - dolutegravir, abacavir and lamivudine - in a single fixed dose combination ...

Follows recent agreement with ViiV Healthcare in collaboration with Clinton Health Access Initiative to expand reach of pediatric formulation of Abacavir/Lamivudine to resource-limited settings ...

Viatris Inc. received a US Food and Drug Administration (FDA) tentative approval for a New Drug Application for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the ...

Capsule formulations are a useful and popular way to create a dosage form that can be developed in a shorter timescale than other dosage forms. Additionally, they are easy to manufacture and are ...

Formulation characteristics must be optimized, following device selection, to achieve the desired performance for the capsule loaded in the dry powder inhaler. Capsules used in dry powder inhalers ...

The fixed dose combination of abacavir and lamivudine tablets for oral suspension 60 mg/30 mg and 120 mg/60 mg is indicated for the treatment of HIV-1 infection in combination with other ...

Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children ...

Abacavir and lamivudine is not recommended in patients with creatinine clearance less than 50 mL per min. Abacavir and lamivudine are contraindicated for patients with hepatic impairment.